NCT02612311 2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3 Terminated
TG Therapeutics, Inc.
Jewish General Hospital
Hoffmann-La Roche
Novartis
Hoffmann-La Roche
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gilead Sciences
Teva Branded Pharmaceutical Products R&D, Inc.